Horizon Pharma Announces Receipt of Fifth U.S. Patent Allowance for DUEXIS(R)

Horizon Pharma Announces Receipt of Fifth U.S. Patent Allowance for DUEXIS(R) 
DEERFIELD, IL -- (Marketwired) -- 05/29/13 --  Horizon Pharma, Inc.
(NASDAQ: HZNP) announced today that it has received a Notice of
Allowance (NOA) from the United States Patent and Trademark Office
(USPTO) for U.S. Patent Application Serial No. 13/620141 entitled
"Stable Compositions of Famotidine and Ibuprofen" with claims that
cover DUEXIS(R) (ibuprofen and famotidine) tablets. DUEXIS is
indicated for the relief of signs and symptoms of rheumatoid
arthritis and osteoarthritis and to decrease the risk of developing
upper gastrointestinal ulcers. 
The Notice of Allowance concludes the substantive examination of this
U.S. patent application and will result in the issuance of a U.S.
patent after administrative processes are completed. The U.S. patent
scheduled to issue from this application will expire in 2028. After
issuance, Horizon plans to list the U.S. patent in the FDA's Approved
Drug Products with Therapeutic Equivalence Evaluations, or Orange
"This is the fifth Notice of Allowance in the U.S. for DUEXIS and
represents yet another important expansion of its patent estate,"
said Timothy P. Walbert, chairman, president and chief executive
officer, Horizon Pharma. "Horizon's goal is to protect the innovation
and commercial potential of DUEXIS and this Notice of Allowance,
along with the previous patents issued, further strengthens our
DUEXIS, a proprietary single-tablet combination of the NSAID
ibuprofen and the histamine H2-receptor antagonist famotidine, is
indicated for the relief of signs and symptoms of rheumatoid
arthritis and osteoarthritis and to decrease the risk of developing
upper gastrointestinal ulcers, which in the clinical trials was
defined as a gastric and/or duodenal ulcer, in patients who are
taking ibuprofen for those indications. The clinical trials primarily
enrolled patients less than 65 years of age without a prior history
of gastrointestinal ulcer. Controlled trials do not extend beyond 6
months. For more information, please visit www.DUEXIS.com.  
Important Safety Information About DUEXIS 
DUEXIS is not right for everyone. People who have had asthma, hives,
or an allergic reaction to aspirin or other NSAIDs should not take
DUEXIS. Women in the late stages of pregnancy should not take DUEXIS.
People who have had allergic reactions to medications like famotidine
(histamine H2-receptor antagonists) should not take DUEXIS. 
Tell your health care provider right away if you have signs of active
bleeding (persistent and unexplained) while you are taking DUEXIS. 
NSAID-containing medications like DUEXIS can cause high blood
pressure or make existing high blood pressure worse, either of which
can increase the chance of a heart attack or stroke. Your health care
provider should check your blood pressure while you are taking
Before you start taking DUEXIS, tell your health care provider if you
have heart problems, kidney problems, or liver problems, or if you
are taking medications for high blood pressure. DUEXIS can increase
the chance of potentially significant liver injury and/or kidney
injury, which may be fatal. Stop taking DUEXIS immediately and
contact your health care provider if you experience any signs and/or
symptoms of liver or kidney injury. 
Serious allergic reactions, including skin reactions, can happen
without warning and can be life threatening. Stop taking DUEXIS and
consult your doctor immediately if you get a skin rash or if you
start to have problems breathing or swallowing or if you develop
swelling of your face or throat. 
The most common side effects of DUEXIS include nausea, diarrhea,
constipation, upper abdominal pain and headache. 
Please see Medication Guide and full Prescribing Information,
available at www.DUEXIS.com. 
About Horizon Pharma 
Horizon Pharma, Inc. is a specialty pharmaceutical company that has
developed and is commercializing DUEXIS and RAYOS/LODOTRA, both of
which target unmet therapeutic needs in arthritis, pain and
inflammatory diseases. The Company's strategy is to develop, acquire,
in-license and/or co-promote additional innovative medicines where it
can execute a targeted commercial strategy in specific therapeutic
areas while taking advantage of its commercial strengths and the
infrastructure the Company has put in place. For more information,
please visit www.horizonpharma.com. 
Forward-Looking Statements 
This press release contains forward-looking statements, including
statements regarding the issuance of a patent based on the notice of
allowance from the U.S. Patent and Trademark Office and the ability
to protect the innovation of and commercial potential of DUEXIS.
These forward-looking statements are based on management's
expectations and assumptions as of the date of this press release,
and actual results may differ materially from those in these
forward-looking statements as a result of various factors. These
factors include risks regarding whether the administrative processes
required for the issuance of patents as indicated in the notices of
allowance will be completed in a timely matter or at all, whether the
patents, if issued as indicated in the notices of allowance, will
provide sufficient protection and market exclusivity for DUEXIS,
whether any patents issued to Horizon may be challenged, invalidated,
infringed or circumvented by third parties and other factors
described in Horizon's filings with the United States Securities and
Exchange Commission, including those factors discussed under the
caption "Risk Factors" in those filings. Forward-looking statements
speak only as of the date of this press release, and Horizon
undertakes no obligation to update or revise these statements, except
as may be required by law. 
Robert J. De Vaere
Executive Vice President, Chief Financial Officer
Kathy Galante
Burns McClellan, Inc.
Press spacebar to pause and continue. Press esc to stop.